Clinical Reminders in Test Reports to Improve Guideline Compliance

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT00414401
First received: December 19, 2006
Last updated: February 6, 2014
Last verified: December 2006
  Purpose

Although beta-blockers are known to prolong survival for patients with reduced left ventricular ejection fraction, their use in the community and the VA is suboptimal.


Condition Intervention
Heart Failure, Congestive
Behavioral: Clinical Reminder

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Clinical Reminders in Test Reports to Improve Guideline Compliance

Resource links provided by NLM:


Further study details as provided by Department of Veterans Affairs:

Primary Outcome Measures:
  • Prescription for any beta-blocker [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Prescription for carvedilol or metoprolol succinate [ Designated as safety issue: No ]

Estimated Enrollment: 1500
Study Start Date: May 2001
Study Completion Date: June 2006
Arms Assigned Interventions
Arm 1 Behavioral: Clinical Reminder

Detailed Description:

Background:

Although beta-blockers are known to prolong survival for patients with reduced left ventricular ejection fraction, their use in the community and the VA is suboptimal.

Objectives:

To determine if a reminder attached to the echocardiography report would increase the use of beta-blockers among patients with depressed left ventricular function.

Methods:

We are randomizing consecutive patients undergoing echocardiography at one of three VA echocardiography laboratories with reduced left ventricular ejection fraction (<40%) and no echocardiographic contraindication to beta-blockers (e.g. aortic stenosis) to a reminder for use of beta-blockers or to no reminder. The reminder gives starting doses for two commonly used beta-blockers (carvedilol and metoprolol). Patients are excluded from the analysis if they leave the health care system or die within three months of randomization. The primary outcome is a prescription for a beta-blocker between three and nine months following echocardiography

Status:

The project is complete.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Those undergoing echocardiography at one of the participating laboratories with an ejection fraction < 45%.

Exclusion Criteria:

aortic stenosis, mitral stenosis

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00414401

Locations
United States, California
VA Palo Alto Health Care System
Palo Alto, California, United States, 94304-1207
Sponsors and Collaborators
Investigators
Principal Investigator: Paul A. Heidenreich, MD MS VA Palo Alto Health Care System
  More Information

Publications:
Responsible Party: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT00414401     History of Changes
Other Study ID Numbers: IIR 01-108
Study First Received: December 19, 2006
Last Updated: February 6, 2014
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on April 17, 2014